Clinical trial
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer (CARAVAGGIO)
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer (CARAVAGGIO)
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 1168 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
Actual Study Start Date: April 13, 2017
Actual Primary Completion Date: June 1, 2019
Estimated Study Completion Date: December 1, 2019
Arms:
- Experimental: Apixaban
- Active Comparator: Dalteparin
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 1168 |
| Study start date | 13 April 2017 |
| Estimated study completion date | 01 December 2019 |